In another study, a panel of 15 genes involved in immune checkpoint and activation pathways, including IFNG, CXCL9, CXCL10, CD8A, perforin 1 (PRF1), granzyme B (GZMB), PD-1, PD-L1, PD-L2, CTLA4, CD80, CD86, LAG3, TIM3, and B and T-lymphocyte-associated (BTLA), was identified as a predictor of melanoma patient response to ICIs [86]. This evidence concerns the gene CXCL10 and melanoma.